Sonnet BioTherapeutics Holdings, Inc.
SONN
$1.16
-$0.01-0.86%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.00M | 1.00M | 18.60K | 55.90K | 92.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00M | 1.00M | 18.60K | 55.90K | 92.80K |
| Cost of Revenue | 1.07M | 1.35M | 109.30K | -5.31M | -4.63M |
| Gross Profit | -69.00K | -351.40K | -90.70K | 5.37M | 4.72M |
| SG&A Expenses | 8.08M | 7.44M | 6.13M | 5.95M | 5.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.78M | 14.42M | 11.87M | 12.33M | 12.76M |
| Operating Income | -13.78M | -13.42M | -11.85M | -12.28M | -12.66M |
| Income Before Tax | -13.13M | -9.27M | -7.44M | -7.99M | -8.43M |
| Income Tax Expenses | 158.40K | 158.40K | -- | -- | -- |
| Earnings from Continuing Operations | -13.29 | -9.43 | -7.44 | -7.99 | -8.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.29M | -9.43M | -7.44M | -7.99M | -8.43M |
| EBIT | -13.78M | -13.42M | -11.85M | -12.28M | -12.66M |
| EBITDA | -13.77M | -13.41M | -11.84M | -12.26M | -12.65M |
| EPS Basic | -11.35 | -9.82 | -10.72 | -24.14 | -42.21 |
| Normalized Basic EPS | -7.04 | -6.09 | -6.70 | -15.09 | -26.38 |
| EPS Diluted | -11.35 | -9.86 | -10.76 | -24.18 | -42.25 |
| Normalized Diluted EPS | -7.04 | -6.11 | -6.72 | -15.11 | -26.40 |
| Average Basic Shares Outstanding | 7.51M | 4.17M | 2.62M | 1.90M | 1.44M |
| Average Diluted Shares Outstanding | 7.51M | 4.20M | 2.66M | 1.93M | 1.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |